Uncertainty and excitement surround one company’s cell therapy for epilepsy
After 10 years of work, Neurona may have the data to quiet its skeptics. But its ongoing clinical trial will be the ultimate test.
Efforts to ease the symptoms of autism are beginning to ramp up, with promising candidates in various stages of testing.
After 10 years of work, Neurona may have the data to quiet its skeptics. But its ongoing clinical trial will be the ultimate test.
The leader of the Frank Porter Graham Child Development Institute talks about what drew him into the autism field, and his departure from — and return to — the University of North Carolina at Chapel Hill.
This month’s Going on Trial newsletter explores how eye tracking might be used beyond helping with diagnosis, among other drug development news.
An imbalance in the number of excitatory neurons in early brain development may account for the difference.
A new individualized approach to transcranial magnetic stimulation may one day be an effective treatment for social and communication difficulties, if the results from Duan’s small preliminary trial pan out.
The Holland Bloorview clinician and research director discusses how growing up on a small island shaped her career and the existential questions that keep her up at night.
This month’s Going on Trial newsletter dives into an electroencephalography biomarker that could track the efficacy of treatments for dup15q and Angelman syndromes, among other drug development news.
Despite grave side effects, it’s vital to keep developing treatments for rare genetic forms of childhood epilepsy, says West, president of the KCNT1 Epilepsy Foundation and father of a son with the condition.
The experienced clinician discusses writing his recent paper, and its reception in the field.
The new devices, which monitor neural activity from within blood vessels, show long-term stability in rats and could one day deliver electrical stimulation.